Bydureon, Bydureon Bcise, Bydureon Pen, Byetta (exenatide) is a protein pharmaceutical. Exenatide was first approved as Bydureon on 2005-04-28. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor. Bydureon's patents are valid until 2030-10-04 (FDA).
|Trade Name||Bydureon, Byetta|
|Indication||type 2 diabetes mellitus|